Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

1 Correction to: Applied Health Economics and Health Policy https://doi.org/10.1007/s40258-022-00726-z

The article “Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting”, written by Sara Staford, Peter G. Bech, Adam Fridhammar , Nino Miresashvili, Andreas Nilsson, Michael Willis and Aiden Liu was originally published electronically on the publisher’s internet portal on 28^th March 2022 without open access.

With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 1^st April 2022 to © The Author(s) 2022 and the article is forthwith distributed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc/4.0/.

The original article has been corrected.